协同刺激分子B7H3与B7H4联合效应对胃癌患者预后影响.pdfVIP

协同刺激分子B7．113与B7．H4联合效心对胃癌患者预后的影响 中文摘要 协同刺激分子B7一H3与B7．H4联合效应对 胃癌患者预后的影响 中文摘要 目的：探讨胃癌组织中协同刺激分子B7一H3、B7一H4表达水平对胃癌患者预后的 影响及与临床病理特征的关系。 方法：采用回顾性研究随访调查157例胃癌患者的相关临床资料：应用免疫组织 化学染色检测相关病理指标及胃癌患者手术标本中B7一H3、B7一H4的表达；胃癌患者 不同临床特征与B7一H3、B7．H4表达水平的相关性采用}方检验，不同临床特征患者 的无进展生存期(Progression—free survival，PFS)及总生存期(Overall survival，os)l拘比 较采用Kaplan．Meier法及Log．rank检验，拟合多因素Cox模型，用HR(Hazard Riskl 及95％CI估计不同临床指标与复发和死亡结局的联系强度。 结果：B7一H3、B7一H4表达水平与不同临床特征之间无明显相关；单因素生存分 析显示年龄较大(60岁)、分期较晚、肿瘤较大(5cm)、浸润较深(侵及深肌层)、远处 转移及协同刺激分子B7一H4高表达等显著减少PFS及OS(P0．05)；多因素Cox模型 分析提示，与I期相比IV期胃癌患者复发和死亡的风险比HR分别为6．20(95％CI： 1．31—29．34)，5．58(95％CI：1．27．24．58)；与肿瘤直径5cm的肿瘤患者相比，肿瘤直径 5cm的肿瘤患者其为1．97(95％Ch 1．19—3．25)，1．95(95％Ch 1．20．3．18)；相对于其他 表达组，B7．H3低表达且B7一H4高表达胃癌患者复发和死亡的风险比HR分别为 1．92f95％Ch 1．20—3．10)，1．93(95％Ch 1．19-3．10)。 结论：B7一H3、B7．H4不同表达水平对胃癌患者PFS和OS有显著影响。两指标 联合对胃癌预后判断可能更有意义。 关键词：胃癌；预后；B7一H3：B7一H4 作 者：徐斌 指导老师：沈月平 英文摘要 协同刺激分子B7．H3 fj B7一H4联合效J、疆对胃痛患者预后的影响 Research of the different expression levels of B7一H3 and B7一H4 in gastric cancer tissue which indicate the different prognosis Abstract Objeetive：To investigate the correlation between the expression level of costimulatory molecules B7一H3．B7一H4 and prognosis value in patients with gastric cancer． Methods：A retrospective study was performed to investigate the clinical data of 1 57 patients with gastric cancer．Expression level of pathological indicators and B7一H3，B7一H4 were detected by the method of immunohistochemical．The correlation between different expression level of B7一H3．B7-H4 and clinical characteristics were tested by chi-square test．PFS and OS of different clinical and pathological characteristics were compared using Kaplan—Meier and Log·rank test；The Cox proportional hazards model was performed to estimate职(Hazard Risk)with 95％CI(confidence interval)of the linking strength between the different clinical characteristics，expressions of B7一H3 and B7一H4 and recurrence，death risks． Results：There was no obvious correlation between B7-H3．B7一H4 expression levels and t